secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2026-08-07T12:35:15+00:00
Accession:  0001683168-26-006077
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Q2 2026 net loss $0.9M; royalty revenue up 12% to $0.7M
---------------------------------------------------------------

- Net loss $0.9M vs $0.7M Q2 2025; cash $6.5M at June 30, 2026 vs $7.9M at Dec 31, 2025.
- Royalty revenue $0.7M, +12% YoY, from Takeda sublicense; first-half royalties ~$1.5M.
- R&D expenses $0.6M (-16% YoY); G&A $1.1M (+64%) on strategic review legal costs.
- ASCO data: DNase I enhanced CAR T expansion, persistence, tumor control; PeriNess study approved for LBCL.
- Strategic review process ongoing; interim CEO James Parslow emphasizes disciplined capital allocation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/0001683168-26-006077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-006077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer